Literature DB >> 26313650

Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Joshua A Lile1, Michael J Wesley, Thomas H Kelly, Lon R Hays.   

Abstract

The aim of the present study was to examine a potential mechanism of action of gabapentin to manage cannabis-use disorders by determining the interoceptive effects of gabapentin in cannabis users discriminating [INCREMENT]-tetrahydrocannabinol ([INCREMENT]-THC) using a pharmacologically selective drug-discrimination procedure. Eight cannabis users learned to discriminate 30 mg oral [INCREMENT]-THC from placebo and then received gabapentin (600 and 1200 mg), [INCREMENT]-THC (5, 15, and 30 mg), and placebo alone and in combination. Self-report, task performance, and physiological measures were also collected. [INCREMENT]-THC served as a discriminative stimulus, produced positive subjective effects, elevated heart rate, and impaired psychomotor performance. Both doses of gabapentin substituted for the [INCREMENT]-THC discriminative stimulus and engendered subjective and performance-impairing effects that overlapped with those of [INCREMENT]-THC when administered alone. When administered concurrently, gabapentin shifted the discriminative-stimulus effects of [INCREMENT]-THC leftward/upward, and combinations of [INCREMENT]-THC and gabapentin generally produced larger effects on cannabinoid-sensitive outcomes relative to [INCREMENT]-THC alone. These results suggest that one mechanism by which gabapentin might facilitate cannabis abstinence is by producing effects that overlap with those of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26313650      PMCID: PMC4769128          DOI: 10.1097/FBP.0000000000000187

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  56 in total

1.  Effects of gabapentin on anxiety induced by simulated public speaking.

Authors:  Fernanda de-Paris; Marcia K Sant'Anna; Monica R M Vianna; Tatiana Barichello; Joao V Busnello; Flavio Kapczinski; Joao Quevedo; Ivan Izquierdo
Journal:  J Psychopharmacol       Date:  2003-06       Impact factor: 4.153

Review 2.  Pharmacotherapy for tobacco dependence.

Authors:  Reginald V Fant; August R Buchhalter; Albert C Buchman; Jack E Henningfield
Journal:  Handb Exp Pharmacol       Date:  2009

3.  A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Authors:  Barbara J Mason; Rebecca Crean; Vivian Goodell; John M Light; Susan Quello; Farhad Shadan; Kimberly Buffkins; Mark Kyle; Murali Adusumalli; Adnan Begovic; Santosh Rao
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

4.  A model for evaluation of antianxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam.

Authors:  S Nakano; H K Gillespie; L E Hollister
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

5.  Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.

Authors:  O A Petroff; F Hyder; D L Rothman; R H Mattson
Journal:  Epilepsia       Date:  2000-06       Impact factor: 5.864

6.  An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.

Authors:  Jennifer A Bestard; Cory C Toth
Journal:  Pain Pract       Date:  2010-11-18       Impact factor: 3.183

Review 7.  Effects of cannabinoids on neurotransmission.

Authors:  B Szabo; E Schlicker
Journal:  Handb Exp Pharmacol       Date:  2005

8.  The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.

Authors:  Mark A Ware; Mary-Ann Fitzcharles; Lawrence Joseph; Yoram Shir
Journal:  Anesth Analg       Date:  2009-12-10       Impact factor: 5.108

9.  Gabapentin treatment for alcohol dependence: a randomized clinical trial.

Authors:  Barbara J Mason; Susan Quello; Vivian Goodell; Farhad Shadan; Mark Kyle; Adnan Begovic
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

10.  Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans.

Authors:  L D Chait; J P Zacny
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more
  5 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 2.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

3.  Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.

Authors:  James J Prisciandaro; William Mellick; Lindsay M Squeglia; Sara Hix; Lauren Arnold; Bryan K Tolliver
Journal:  Addict Biol       Date:  2021-08-14       Impact factor: 4.093

4.  (-)-Trans-Δ9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2016-02-10

5.  Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice.

Authors:  M L Eckard; S G Kinsey
Journal:  Neuropharmacology       Date:  2021-04-15       Impact factor: 5.273

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.